The US Bankruptcy Court gave an order approving the sale of certain assets of Diadexus, Inc. on June 8, 2018. The debtor has been authorized to sell its certain assets to Leap Tide Capital Management, LLC, pursuant to the asset purchase agreement dated May 8, 2018. The debtor’s assets include estate’s right, title and interest and certain litigation assets against former Officers and Directors. In exchange as consideration, debtor will receive 80% net recoveries on the litigation rights. The debtor did not receive any other competing bids for the purchase of its assets and therefore Leap Tide Capital Management, LLC emerged as the winning bidder.
Diadexus, Inc. is a diagnostics company. The Company is engaged in developing and commercializing products that deliver healthcare providers with relevant information to assist in the management of patients throughout the course of cardiac disease. Its capabilities include manufacturing, assay development, Food and Drug Administration (FDA) regulatory clearance, and marketing and selling products. Its commercially-available products consist of two FDA-cleared tests to measure Lp-PLA2: the PLAC Test ELISA Kit (the PLAC ELISA Test) and the PLAC Test for Lp-PLA2 Activity (the PLAC Activity Test). Its other products include proADM; proET-1, which aids in predication of heart failure, and proANP, which aids in predication of heart failure. The Company sells its diagnostic products to laboratories and promotes these products to the laboratories' sales representatives, as well as directly to healthcare providers.
DIADEXUS, INC. 
